Cargando…
Thiol/Redox Metabolomic Profiling Implicates GSH Dysregulation in Early Experimental Graft versus Host Disease (GVHD)
Graft-versus-host disease (GVHD) is a common complication of allogeneic bone marrow transplantation (BMT). Upregulation of inflammatory cytokines precedes the clinical presentation of GVHD and predicts its severity. In this report, thiol/redox metabolomics was used to identify metabolic perturbation...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928313/ https://www.ncbi.nlm.nih.gov/pubmed/24558439 http://dx.doi.org/10.1371/journal.pone.0088868 |
_version_ | 1782304240650158080 |
---|---|
author | Suh, Jung H. Kanathezhath, Bindu Shenvi, Swapna Guo, Hua Zhou, Alicia Tiwana, Anureet Kuypers, Frans Ames, Bruce N. Walters, Mark C. |
author_facet | Suh, Jung H. Kanathezhath, Bindu Shenvi, Swapna Guo, Hua Zhou, Alicia Tiwana, Anureet Kuypers, Frans Ames, Bruce N. Walters, Mark C. |
author_sort | Suh, Jung H. |
collection | PubMed |
description | Graft-versus-host disease (GVHD) is a common complication of allogeneic bone marrow transplantation (BMT). Upregulation of inflammatory cytokines precedes the clinical presentation of GVHD and predicts its severity. In this report, thiol/redox metabolomics was used to identify metabolic perturbations associated with early preclinical (Day+4) and clinical (Day+10) stages of GVHD by comparing effects in Syngeneic (Syn; major histocompatibility complex- identical) and allogeneic transplant recipients (Allo BMT) in experimental models. While most metabolic changes were similar in both groups, plasma glutathione (GSH) was significantly decreased, and GSH disulfide (GSSG) was increased after allogeneic compared to syngeneic recipient and non-transplant controls. The early oxidation of the plasma GSH/GSSG redox couple was also observed irrespective of radiation conditioning treatment and was accompanied by significant rise in hepatic protein oxidative damage and ROS generation. Despite a significant rise in oxidative stress, compensatory increase in hepatic GSH synthesis was absent following Allo BMT. Early shifts in hepatic oxidative stress and plasma GSH loss preceded a statistically significant rise in TNF-α. To identify metabolomic biomarkers of hepatic GVHD injury, plasma metabolite concentrations analyzed at Day+10 were correlated with hepatic organ injury. GSSG (oxidized GSH) and β-alanine, were positively correlated, and plasma GSH cysteinylglycine, and branched chain amino acids were inversely correlated with hepatic injury. Although changes in plasma concentrations of cysteine, cystathionine (GSH precursors) and cysteinylglycine (a GSH catabolite) were not significant by univariate analysis, principal component analysis (PCA) indicated that accumulation of these metabolites after Allo BMT contributed significantly to early GVHD in contrast to Syn BMT. In conclusion, thiol/redox metabolomic profiling implicates that early dysregulation of host hepatic GSH metabolism and oxidative stress in sub-clinical GVHD before elevated TNF-α levels is associated with GVHD pathogenesis. Future studies will probe the mechanisms for these changes and examine the potential of antioxidant intervention strategies to modulate GVHD. |
format | Online Article Text |
id | pubmed-3928313 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-39283132014-02-20 Thiol/Redox Metabolomic Profiling Implicates GSH Dysregulation in Early Experimental Graft versus Host Disease (GVHD) Suh, Jung H. Kanathezhath, Bindu Shenvi, Swapna Guo, Hua Zhou, Alicia Tiwana, Anureet Kuypers, Frans Ames, Bruce N. Walters, Mark C. PLoS One Research Article Graft-versus-host disease (GVHD) is a common complication of allogeneic bone marrow transplantation (BMT). Upregulation of inflammatory cytokines precedes the clinical presentation of GVHD and predicts its severity. In this report, thiol/redox metabolomics was used to identify metabolic perturbations associated with early preclinical (Day+4) and clinical (Day+10) stages of GVHD by comparing effects in Syngeneic (Syn; major histocompatibility complex- identical) and allogeneic transplant recipients (Allo BMT) in experimental models. While most metabolic changes were similar in both groups, plasma glutathione (GSH) was significantly decreased, and GSH disulfide (GSSG) was increased after allogeneic compared to syngeneic recipient and non-transplant controls. The early oxidation of the plasma GSH/GSSG redox couple was also observed irrespective of radiation conditioning treatment and was accompanied by significant rise in hepatic protein oxidative damage and ROS generation. Despite a significant rise in oxidative stress, compensatory increase in hepatic GSH synthesis was absent following Allo BMT. Early shifts in hepatic oxidative stress and plasma GSH loss preceded a statistically significant rise in TNF-α. To identify metabolomic biomarkers of hepatic GVHD injury, plasma metabolite concentrations analyzed at Day+10 were correlated with hepatic organ injury. GSSG (oxidized GSH) and β-alanine, were positively correlated, and plasma GSH cysteinylglycine, and branched chain amino acids were inversely correlated with hepatic injury. Although changes in plasma concentrations of cysteine, cystathionine (GSH precursors) and cysteinylglycine (a GSH catabolite) were not significant by univariate analysis, principal component analysis (PCA) indicated that accumulation of these metabolites after Allo BMT contributed significantly to early GVHD in contrast to Syn BMT. In conclusion, thiol/redox metabolomic profiling implicates that early dysregulation of host hepatic GSH metabolism and oxidative stress in sub-clinical GVHD before elevated TNF-α levels is associated with GVHD pathogenesis. Future studies will probe the mechanisms for these changes and examine the potential of antioxidant intervention strategies to modulate GVHD. Public Library of Science 2014-02-18 /pmc/articles/PMC3928313/ /pubmed/24558439 http://dx.doi.org/10.1371/journal.pone.0088868 Text en © 2014 Suh et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Suh, Jung H. Kanathezhath, Bindu Shenvi, Swapna Guo, Hua Zhou, Alicia Tiwana, Anureet Kuypers, Frans Ames, Bruce N. Walters, Mark C. Thiol/Redox Metabolomic Profiling Implicates GSH Dysregulation in Early Experimental Graft versus Host Disease (GVHD) |
title | Thiol/Redox Metabolomic Profiling Implicates GSH Dysregulation in Early Experimental Graft versus Host Disease (GVHD) |
title_full | Thiol/Redox Metabolomic Profiling Implicates GSH Dysregulation in Early Experimental Graft versus Host Disease (GVHD) |
title_fullStr | Thiol/Redox Metabolomic Profiling Implicates GSH Dysregulation in Early Experimental Graft versus Host Disease (GVHD) |
title_full_unstemmed | Thiol/Redox Metabolomic Profiling Implicates GSH Dysregulation in Early Experimental Graft versus Host Disease (GVHD) |
title_short | Thiol/Redox Metabolomic Profiling Implicates GSH Dysregulation in Early Experimental Graft versus Host Disease (GVHD) |
title_sort | thiol/redox metabolomic profiling implicates gsh dysregulation in early experimental graft versus host disease (gvhd) |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928313/ https://www.ncbi.nlm.nih.gov/pubmed/24558439 http://dx.doi.org/10.1371/journal.pone.0088868 |
work_keys_str_mv | AT suhjungh thiolredoxmetabolomicprofilingimplicatesgshdysregulationinearlyexperimentalgraftversushostdiseasegvhd AT kanathezhathbindu thiolredoxmetabolomicprofilingimplicatesgshdysregulationinearlyexperimentalgraftversushostdiseasegvhd AT shenviswapna thiolredoxmetabolomicprofilingimplicatesgshdysregulationinearlyexperimentalgraftversushostdiseasegvhd AT guohua thiolredoxmetabolomicprofilingimplicatesgshdysregulationinearlyexperimentalgraftversushostdiseasegvhd AT zhoualicia thiolredoxmetabolomicprofilingimplicatesgshdysregulationinearlyexperimentalgraftversushostdiseasegvhd AT tiwanaanureet thiolredoxmetabolomicprofilingimplicatesgshdysregulationinearlyexperimentalgraftversushostdiseasegvhd AT kuypersfrans thiolredoxmetabolomicprofilingimplicatesgshdysregulationinearlyexperimentalgraftversushostdiseasegvhd AT amesbrucen thiolredoxmetabolomicprofilingimplicatesgshdysregulationinearlyexperimentalgraftversushostdiseasegvhd AT waltersmarkc thiolredoxmetabolomicprofilingimplicatesgshdysregulationinearlyexperimentalgraftversushostdiseasegvhd |